

DEPARTMENT OF COMMERCE Patent and Trad mark Offic

Addr ss: COMMISSIONER OF PATENTS AND TRADEMARKS
Washington, D.C. 20231

	APPLICATION NO.	FILING DATE	FIRST NAMED INVENTOR			ATTORNEY DOCKET NO.
	09/252,82	28 02/19/	99 DONG		ĸ	024754/0114
Γ	_	HM22/0912			EXAMINER	
	FOLEY & LARDNER			7 L £.	COOK,L	
	3000 K ST	REET N W	•		ART UNIT	PAPER NUMBER
	SUITE 500 WASHINGTO) JN DC 20007	-8696		1641	13
						09/12/00

Please find below and/or attached an Office communication concerning this application or proceeding.

Commissioner of Patents and Trad marks

Office Action Summary

Application No. **09/252,828**

Applican(s)

Dong et al.

Examiner

Lisa V. Cook

Group Art Unit 1641



X Responsive to communication(s) filed on <u>Jun 28, 2000</u>					
☐ This action is FINAL .					
Since this application is in condition for allowance except for formal matters, prosecution as to the merits is closed in accordance with the practice under Ex parte Quay/835 C.D. 11; 453 O.G. 213.					
A shortened statutory period for response to this action is set to expire					
Disposition of Claim					
Of the above, claim(s) is/are withdrawn from consideration					
Claim(s) is/are allowed.					
Claim(s) is/are rejected.					
Claim(s) is/are objected to.					
Application Papers See the attached Notice of Draftsperson's Patent Drawing Review, PTO-948. The drawing(s) filed on is/are objected to by the Examiner. The proposed drawing correction, filed on isapproveddisapproved. The specification is objected to by the Examiner. The oath or declaration is objected to by the Examiner. Priority under 35 U.S.C. § 119 Acknowledgement is made of a claim for foreign priority under 35 U.S.C. § 119(a)-(d).					
☐ All ☐Some* None of the CERTIFIED copies of the priority documents have been ☐ received.					
☐ received.					
received in this national stage application from the International Bureau (PCT Rule 17.2(a)). *Certified copies not received:					
☐ Acknowledgement is made of a claim for domestic priority under 35 U.S.C. § 119(e).					
Attachment(s) Notice of References Cited, PTO-892 Information Disclosure Statement(s), PTO-1449, Paper No(s). Interview Summary, PTO-413 Notice of Draftsperson's Patent Drawing Review, PTO-948 Notice of Informal Patent Application, PTO-152					
SEE OFFICE ACTION ON THE FOLLOWING PAGES					

Application/Control Number: 09/252,828

Art Unit: 1641

DETAILED ACTION

Election/Restrictions

1. The amendment filed on 6/28/00 canceling all claims drawn to the elected invention and presenting only claims drawn to a non-elected invention is non-responsive (MPEP § 821.03). The remaining claims are not readable on the elected invention because claims 28, 36, 37, 38, and 41 are drawn to a plurality of disclosed patentably distinct inventions (glycopolypeptides comprising materially different amino acid sequences as evidence by separate amino acid position substitutions). These separate glycopolypeptides bear distinct structural or biochemical properties as substantiated by the separate amino acid substitution positions thereby having different binding characteristic and functionality. Therefore, each disclosed patentably distinct glycopolypeptide is considered a separate invention and changes the scope of the previously elected invention.

Since the above-mentioned amendment appears to be a *bona fide* attempt to reply, applicant is given a TIME PERIOD of ONE (1) MONTH or THIRTY (30) DAYS, whichever is longer, from the mailing date of this notice within which to supply the omission or correction in order to avoid abandonment. EXTENSIONS OF THIS TIME PERIOD UNDER 37 CFR 1.136(a) ARE AVAILABLE.

Application/Control Number: 09/252,828

Art Unit: 1641

CRF Sequence Non-Compliance

2. This application contains sequence disclosures that are encompassed by the definitions for nucleotide and/or amino acid sequences set forth in 37 CFR 1.821(a)(1) and (a)(2). However, this application fails to comply with the requirements of 37 CFR 1.821 through 1.825 for the reason(s) set forth on the attached Notice To Comply With Requirements For Patent Applications Containing Nucleotide Sequence And/Or Amino Acid Sequence Disclosures. Applicant must comply with the requirements of the sequence rules (37 CFR 1.821 - 1.825) before the application can be examined under 35 U.S.C. §§ 131 and 132. EACH OF THE NOTED SUBSTITUTIONS REQUIRE A SEQUENCE LISTING OF SEQ ID. NO.1 WITH THE VARIATIONS CLAIMED.

Applicant is given ONE MONTH from the mailing date of this communication within which to comply with the sequence rules, 37 CFR 1.821 - 1.825. Failure to comply with these requirements will result in ABANDONMENT of the application under 37 CFR 1.821(g). Extensions of time may be obtained by filing a petition accompanied by the extension fee under the provisions of 37 CFR 1.136(a). Direct the reply to the undersigned. Applicant is requested to return a copy of the attached Notice to Comply with the reply.

3. Papers related to this application may be submitted to Group 1600 by facsimile transmission. Papers should be faxed to Group 1600 via the PTO fax Center located in Crystal Mall 1. The faxing of such papers must conform to the notice published in the Official Gazette, 1096 OG 30 (November 15, 1989). The Group 1641 Fax number is (703) 308-4242, which is able to receive transmissions 24 hours/day, 7 days/week.

Any inquiry concerning this communication or earlier communications from the examiner should be directed to Lisa V. Cook whose telephone number is (703) 305-0808. The examiner can normally be reached on Monday – Friday from 8:00AM – 4:30PM.

If attempts to reach the examiner by telephone are unsuccessful, the examiner's supervisor, Long Le, can be reached on (703) 305-3399.

Any inquiry of a general nature or relating to the status of this application or proceeding should be directed to the receptionist whose telephone number is (703) 308-0196.

Art Unit 1641

CM1-7D16

(703) 305-0808

September 11, 2000

LONG V. LE

SUPERVISORY PATENT EXAMINER

TECHNOLOGY CENTER 1600